


Unveiling Our Strategy for Advancing Innovative Drug Pipelines

January 2025





Disclaimer

This document contains 'forward-looking statements' related to the business performance, market condition, future events, and plan. Therefore, the recipients of this document shall be aware that the forward-looking statements set forth herein may not correspond to the actual business performance of the company due to changes in the business/industry environment and the long-term business plan of the company.

The purpose of this document is not to recommend investment in the company. The company hereby expressly disclaims any liability resulting from investors' reliance on the information contained herein.

Leading the Biosimilar Frontier

“Pioneered the First mAb Biosimilar and Secured Approval for 11 Biosimilars Globally”

With 20 years of Experience in Antibody R&D, Production & Commercialization

Classification	Present (11 products)					2030(E) (22 products)		
 Immunology (12 products)	IV¹ REMSIMA /INFLECTRA (infliximab)	Sub-Q² REMSIMA SC (infliximab)	Sub-Q YUFLYMA (adalimumab)	IV/Sub-Q STEQEYMA (ustekinumab)	IV/Sub-Q AVTOZMA (tocilizumab)	IV biosimilar of OCREVUS®	Sub-Q biosimilar of COSENTYX®	+5 Molecules
 Oncology (7 products)	IV TRUXIMA (rituximab)	IV HERZUMA (trastuzumab)	IV VEGZELMA (bevacizumab)			IV biosimilar of KEYTRUDA®		+3 Molecules
 Other therapeutic focus areas (3 products)			Sub-Q OMLYCLO (omalizumab)	IVI³ EYDENZELT (afibercept)	Sub-Q STOBOCLO/ OSENVELT (denosumab)			

Zymfentra

“Zymfentra Poised for Success in the US, Following Remsima Lineup’s Market Leadership in EU ”

Product Competitiveness

First and Only Sub-Q Infliximab

- High efficacy with convenient self-injection

Patent Protection

Patent Protection until 2037–2040

- Formulation patent valid until 2037
- Administration patent valid until 2038-2040


PBM Coverage

Listed on the Formularies of the TOP 3 PBMs
in the US

High Profitability

High WAC¹ and Strong NSP² Positioning
as a Novel Drug

No. of Infliximab Patients & M/S of Remsima IV+SC in EU5




From CMO to
the World's First mAb Biosimilar Developer,
and **Now Evolving into an Innovator**,

What is
Celltrion's Competitive Edge?



Innovative Drug Development Strategy



Our ADC Journey: From Best-in-Class to Next-Generation

Next-gen ADC

Dual-payload ADC


Achieving synergistic efficacy or extended therapeutic effects through innovative payload pairings

Bispecific ADC

Overcoming cancer heterogeneity through dual or multi-antigen targeting

Biobetter ADC

Improving therapeutic index through bystander effect




Biobetter ADC

- High DAR, low potency: Driving efficacy with a balanced approach

 In development


Low DAR ▶ High DAR

Objective Response Rate



34.2%


79.7%



Bispecific ADC


- Advanced bispecific engineering: Enhancing efficacy and expanding target patient

Asymmetric Bispecific ADC



 In development

Tetravalent(2+2) Bispecific ADC




Dual-payload ADC

- Strategic payload pairing: Synergistic and resistance-overcoming approach

 In development

Complementary MoAs¹ (Synergistic)


Topoisomerase 1 inhibitor (DXd)
+ DNA Damage Response inhibitor (DDRi)



 In development

Independent MoAs (Resistance-overcoming)

Topoisomerase 1 inhibitor (DXd)
+ Microtubule inhibitor (MTi)



| Pioneering the Future of Multispecific Antibody

Next-gen MsAb

Other Immuno-oncology MsAb


Maximizing therapeutic potential of tumor killing immune cells

Conditionally-active MsAb

Expanding killing ability to low expressing cancer cells, thereby increasing response and broadening the patient population

Tumor-selective MsAb

Overcoming on-target off-tumor toxicity



Tumor-selective Multispecific Antibody

- **Avidity-driven selectivity:** Optimized affinity to avoid on-target off-tumor toxicity



B cell lineage target

- CD20¹-positive B cell depletion
- BCMA²-positive plasma cell depletion
- GPRC5D³-positive plasma cell depletion

Tumor-specific target

- Peptide-HLA⁴-directed CD3 T cell engager
- DLL3⁵-directed CD3 T cell engager

 In development

Overexpressed tumor target
“Affinity ↓ / Valency ↑”



Avidity rescues binding only when
the target density is high


Conditionally-active Multispecific Antibody

- Enhanced tumor selectivity by conditional activation

In development


Antibody masking

Prodrug therapeutic



- ✓ Unmasking by tumor microenvironment protease
- ✓ Irreversible

pH-sensitivity



- ✓ Tumor microenvironment specific character (low pH, High ATP¹) switches binding on/off
- ✓ Reversible

Other Immuno-oncology Multispecific Antibody

 In development

T cell Quality & Quantity

T cell co-stimulation

- Enhance tumor killing
- Enhance T cell expansion
- Prevent loss of function
- Rescue a weak Signal 1

T cell proliferation

- Limited number of T cell in TME
- Cytokines can increase T cell proliferation

Other immune cell engagers


NK¹ cell engager

- Strong tumor killing effect
- Produce less proinflammatory cytokine

Myeloid cell engager

- Tumor-associate macrophage reprogramming
- Cold tumor to Hot tumor
- Antigen spreading
- Aggregated protein phagocytosis

Novel Drug Platform & Drug Pipelines





01

ADC

Antibody-Drug Conjugates

Celltrion's ADC platform : Best-in-class Topo1i, PBX-7016

Increasing need for
Topo1i based payloads



Rising number of clinical studies
for Topo1i Inhibitors with high TI¹

Series of adverse events
in Topo1i studies



Case 1

Company A (USA-based)
restricted the dosage of Topo1i
ADC **to a lower level** following AE
reports in its Topo1i ADC study

Case 2

Company B (Germany-based)
suspended patient recruitment²
for its Topo1i ADC clinical trial
after reports of three deaths



Outstanding Safety



Outstanding Efficacy

Secured Payload PBX-7016


**Celltrion enters
novel ADC development**

Celltrion's ADC platform: Topo1i, PBX-7016

- PBX-7016 ADC demonstrated **low toxicity and high TGI¹** both in vitro & in vivo studies
- PBX-7016 is expected to **demonstrate the most superior clinical efficacy and safety compared to existing DXd analogs**

In Vitro Cytotoxicity Results


● Dxd ● FL118 ● PBX-7016 ● Exatecan



- ✓ PBX-7016 demonstrated low cytotoxicity compared to DXd analog, FL118 and Exatecan
- ➔ The improved safety profile in PBX-7016 is expected to enable high-dosage clinical studies

In Vivo Efficacy Results

● Vehicle² ● Benchmark ● Anti-HER2-PBX7016 3 mpk



- ✓ PBX-7016 ADC demonstrated a **comparable TGI result to that of the competitor**

CT-P70: anti-cMET Topo1i-based ADC

- Anti-cMET Topo1i-based for Solid Tumors - Optimal Payload & Target Combination

Lung Cancer : leading cause of cancer-related deaths

Source: GLOBOCAN 2020




Clinical trials and approved ADCs for NSCLC on the rise

	Topo1 inhibitor ¹	Tublin Inhibitor ¹
Marketed	2	0
Clinical Trial	2	3
Pre-clinical	5+	3

- ✓ Increasing number of ADCs, focusing on lung cancer, are undergoing clinical trials, with payloads categorized into either Topo1 or Tubulin inhibitors

NSCLC ADC Targets & Mechanism of Action

NON-SMALL CELL LUNG CANCER



- ✓ Leading ADC targets for NSCLC: Trop2, HER3, MET, CEACAM5


*Source : Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer Desai, Aakash *et al*/ Lung Cancer, Volume 163, 96 - 106

1. Number of pipelines


CT-P70: anti-cMET Topo1i-based ADC

- Potential Best-in-Class** – CT-P70 demonstrated a superior Therapeutic Index¹ in multiple NSCLC CDX² & PDX³ models, significantly outperforming benchmark drugs⁴ currently in clinical development.

CDX (cMET mid-high)



PDX (cMET H-score 105)



Therapeutic Index Comparison

	Benchmark A	Benchmark B	CT-P70
Development Stage	BLA	Phase ½	Pre-IND
Tolerable Dose in NHP (A)	2.8mg/kg ⁶	30mg/kg ⁷	60mg/kg ⁸
MED (B)	3 mg/kg ~ 10mg/kg	0.3mg/kg ~ 3 mg/kg	0.3mg/kg ~ 3 mg/kg
Therapeutic Index (A/B)	0.28 ~ 0.93	10 ~ 100	20 ~ 200

~100x ↑ ~200x ↑

1. Therapeutic Index: The ratio of the drug's efficacy to its toxicity, indicating the margin of safety. A higher Therapeutic Index reflects greater therapeutic benefit with reduced adverse effects.;

2. CDX: Cell line-derived Xenograft, NCI-H441; 3. PDX: Patient-derived Xenograft, LU-01-1004; 4. Benchmark A (BLA); Benchmark B (Phase 1/2); 5. MED: Minimal Efficacy Dose;


6-7. Assumed tolerable dose from FIH starting dose; 8. Tolerable dose level from repeated dose without any lethality from the internal NHP tox study

CT-P71: anti-Nectin4 Topo1i-based ADC

- Demonstrated superior TGI¹ in Nectin-4² overexpressed breast cancer cell lines compared to competitors
- CT-P71 Re-Challenge is ongoing to test anti-cancer activity in animal models where benchmark failed to demonstrate efficacy

In Vitro Cytotoxicity Results


T47D³ (Overexpressing Cell Line)



- ✓ CT-P71 has significantly higher tumor growth inhibition than the isotype, confirming its specific cytotoxicity on Nectin-4 expressing cells

In Vivo Efficacy Results

Key Findings(T47D)



- ✓ CT-P71 demonstrates remarkably higher tumor growth inhibition than the competitor (Benchmark 64.6% vs **CT-P71 90.8%**)

1. TGI: Tumor Growth Inhibition; 2. Nectin-4: a cell adhesion protein that is overexpressed in various solid tumors, including metastatic urothelial carcinoma;
3. T47D: Nectin-4 overexpressing breast cancer cell line; 4. DAR: Drug-to-Antibody Ratio



02

Multispecific Antibody

| Multispecific Antibody : Addressing Unmet Need

Multispecific Antibody Market is Rapidly Growing as it Expands Treatment Options

“ MsAb for Solid Tumors Addressing On-target Off-tumor Toxicity Concerns Needed ”



On-target Off- tumor Toxicity

Absence of tumor-specific antigens (TSA) led to damage to normal cells

Modulating valency and binding affinity to target cancer cells

Enhancing cancer cell targeting via expression differences between normal and cancer cells

Valency UP

Doubling binding sites for efficient tumor targeting

Affinity DOWN

Lowering affinity to reduce toxicity to normal cells



Cytokine Release Storm (CRS)

Excessive cytokine release resulting from overactivated immune system


Preventing overactivation of T-cells

Modulating the binding affinity to CD3 that activates T-cells

Reduce cytokine release by preventing T-cell overactivation and limiting their spread to non-cancerous cells

CT-P72: Bispecific HER2 x CD3 T-cell Engager

- Minimizing on-target-off-tumor toxicity & expanding therapeutic window



Valency (+)	Binding affinity (-)	
2+2 Structure	HER2 Affinity reduction	CD3 Affinity reduction

Reduction in binding to
cells expressing the target
at low density
(i.e., normal cells)



CRS
prevention



Improved delivery
to cancer cells



Effective cancer cell
targeting



CT-P72 : Bispecific HER2 x CD3 T-cell Engager



Aiming to be Best-in-Class

Safety
UP

Maintained efficacy
in HER2 overexpressing
breast cancer cell lines



Demonstrated reduced
toxicity in HER2 low-expressing
breast cancer cell lines

Comparable tumor
growth inhibition (%TGI)



Confirmed
high tolerable dosage

● Benchmark ● CT-P72(10.0)¹ ● CT-P72(10.5.1)²

In-Vitro



In-Vivo




1. CT-P72(10.0) : Binding affinity is not optimized(Parental clone); 2. CT-P72(10.5.1) : Binding affinity is optimized

IND Submission Timelines for Novel Drug Pipelines

● ADC ● Multispecific Antibody

Advancing Innovative Pipeline



1. NSCLC: Non-small cell lung cancer

A 3D rendering of a DNA double helix. The sugar-phosphate backbones are represented by white, glossy spheres. The base pairs are represented by purple rods. Several base pairs are highlighted with glowing, multi-colored (blue, purple, pink) spherical particles, suggesting a focus on specific genetic information or a therapeutic intervention.

Advanced Therapeutics within Everyone's Reach

Thank you